|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In this study, we aimed to determine the association of ERAP1 gene SNPs (rs30187 and rs2287987) with AS risk as well as their effect on the mRNA expression of pro-inflammatory and anti-inflammatory cytokines, with emphasis on the immunoregulation of the IL-17/IL-23 pathway, in an Iranian population.
|
31711818 |
2020 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The IL-17 and IL-23 levels were not different between AS and RA (p = 0.409 and p = 0.562, respectively).
|
31830775 |
2020 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
There were significantly increased mRNA and serum concentrations of both IL-17A and IL-23 in AS patients compared with controls.
|
30740926 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We found that rifaximin significantly reduced the severity of AS and resulted in down-regulation of inflammatory factors, such as TNF-α, IL-6, IL-17A, and IL-23.
|
30886835 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, how the emergent data points towards the efficacy of secukinumab and ixekizumab, a second emergent IL-17A blocker, in AS has helped focus research into the IL-23/17 axis in entheseal driven disease in man and how IL-17A inhibition may be linked to the presence of innate and adaptive immune cell populations capable of IL-17A elaboration in these target tissues.
|
30576610 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Circulating IL-23 and IL-12p40 were raised among AS patients, as some of the genotypes of both IL12B polymorphisms positively regulate their expression.
|
30443744 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We evaluated serum IL-17 and IL-23 levels after 1-year follow-up in AS patients using only nonsteroidal anti inflammatory drugs (at need or continue).
|
31347941 |
2019 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Interleukin 23 (IL-23) pathway and IL-1 cluster genes play prominent role in the etiopathology of ankylosing spondylitis (AS).
|
29200018 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Treatment with risankizumab did not meet the study primary endpoint and showed no evidence of clinically meaningful improvements compared with placebo in patients with active AS, suggesting that IL-23 may not be a relevant driver of disease pathogenesis and symptoms in AS.
|
29945918 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The IL-23/T helper 17 (Th17) axis plays an important role in joint inflammation in ankylosing spondylitis (AS).
|
30057583 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The frequency of gut-derived CX<sub>3</sub> CR1+CD59+CCR9+TL1A+IL-23+ MNPs was significantly higher in the peripheral blood and synovial fluid of AS patients than controls.
|
29869839 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Among these IL-23-regulated miRNAs, the expression levels of miR-29b-1-5p, miR-4449, miR-211-3p, miR-1914-3p, and miR-7114-5p were found to be higher in AS T cells.
|
30463609 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
The unique bone phenotype that occurs in PsA and AS is a surprising coexistence of both systemic bone loss and periosteal and entheseal bone formation and is likely to be the result of the actions of IL-23 and/or IL-17 on bone.
|
30266977 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In this review, several points are discussed and summarized including recent advances on the role of the IL-17/IL-23 immune pathway in the pathogenesis of AS, HLA-B27, and ERAP 1 and 2 mediated pathogenesis, AS-related microbiota compositions, and new potential therapies for AS.
|
29409751 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
There were significant correlations among NLRP3, caspase-1, ASC, IL-1β, IL-17A, and IL-23 expression in patients with AS, except for a weak association between NLRP3 and IL-17A.
|
30138619 |
2018 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
Furthermore, polymorphisms of <i>IL23R</i> are a risk factor for ankylosing spondylitis (AS) and psoriatic arthritis (PsA), which indicates that IL-23 is also involved in the pathogenesis of spondyloarthritis (SpA).
|
28850053 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
RT-qPCR data showed a significant overexpression of HLA-B27, UPR genes (BiP, CHOP, and XBP1), and IL-23 in M-CSF-derived macrophages from AS patients compared to healthy controls.
|
27846758 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Expert opinion: Based on the rationale of the involvement of the IL-23/Th17 axis in AS, novel biological agents have been developed and include secukinumab, an anti-IL-17A agent and ustekinumab, an anti-IL-23 antibody.
|
28099816 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Transcript levels of genes involved in osteoblast function, as well as of the ER stress marker were higher in the AS group than the Ct group, and elevated RUNX2, BiP and IL-23 expression were observed in the BdCs, serum, and bone biopsies from the AS group.
|
28728847 |
2017 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
In particular, therapies targeting the IL-23 pathway were repositioned for use in AS following the discovery of multiple genes in the pathway as determinants of AS risk.
|
27641916 |
2016 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
This review provides an overview of the IL-23/IL-17 pathway in the pathogenesis of AS and summarizes new potential treatments for AS and related inflammatory diseases.
|
26080615 |
2016 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Serum levels of IL-37 were correlated with laboratory values as well as TNF-α, IL-6 and IL-17, but not IL-23 in patients with AS.
|
25627863 |
2015 |
|
Ankylosing spondylitis
|
0.100 |
Biomarker
|
disease |
BEFREE |
Besides TNF, the IL-23/IL-17 axis is emerging as an important inflammatory pathway in SpA, as a SNP in the IL-23R locus has been associated with developing AS, mice overexpressing IL-23 develop SpA-like features and IL-17 blockade has been shown to be efficacious for AS patients in a phase II trial.
|
23969080 |
2014 |
|
Ankylosing spondylitis
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
The subunit of IL-23 (IL12B) and its receptor (IL23R) gene single-nucleotide polymorphisms (SNPs) have been shown to be associated with several autoimmune diseases such as inflammatory bowel disease, psoriasis and ankylosing spondylitis.
|
24547735 |
2014 |
|
Ankylosing spondylitis
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The aim of the study was to clarify the mechanisms underlying the increased IL-23 expression in the gut of AS patients.
|
23740229 |
2014 |